MF498 [N-{[4-(5,9-dethoxy-6-oxo-6,8-dihydro-7H-yrrolo[3,4-g]quinolin-7-yl)- 3-methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a selective E prostanoid receptor 4 antagonist, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis

Journal of Pharmacology and Experimental Therapeutics

Volumn 325, Issue 2, 2008, Pages 425-434

  Clark, Patsy ^a   Rowland, Steven E ^a   Denis, Danielle ^a   Mathieu, Marie Claude ^a   Stocco, Rino ^a   Poirier, Hugo ^a   Burch, Jason ^a   Han, Yongxin ^a   Audoly, Laurent ^a   Therien, Alex G ^a   Xu, Daigen ^a  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 [3 [2 (BENZYLOXY) 5 CHLOROPHENYL] 2 THIENYL]PYRIDIN 3 YL] 2,2,2 TRIFLUOROETHANE 1,1 DIOL; 2 (6 CHLORO 1H PHENANTHRO[9,10 D]IMIDAZOL 2 YL)ISOPHTHALONITRILE; 3 (3,4 DIFLUOROPHENYL) 4 (4 METHYLSULFONYLPHENYL) 2 (5H) FURANONE; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; FREUND ADJUVANT; FUROSEMIDE; INDOMETACIN; IODOACETIC ACID; MF 2661; MF 2663; MF 498; N [(5 BROMO 2 METHOXYPHENYL)SULFONYL] 3 [5 CHLORO 2 (2 NAPHTHYLMETHYL)PHENYL]ACRYLAMIDE; N [[4 (5,9 DIETHOXY 6 OXO 6,8 DIHYDRO 7H PYRROLO[3,4 G]QUINOLIN 7 YL) 3 METHYLBENZYL]SULFONYL] 2 (2 METHOXYPHENYL)ACETAMIDE; PROSTAGLANDIN INHIBITOR; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; CYCLIC AMP; CYCLOOXYGENASE 2; MESSENGER RNA; N ((4 (5,9 DIETHOXY 6 OXO 6,8 DIHYDRO 7H PYRROLO(3,4 G)QUINOLIN 7 YL) 3 METHYLBENZYL)SULFONYL) 2 (2 METHOXYPHENYL)ACETAMIDE; N-((4-(5,9-DIETHOXY-6-OXO-6,8-DIHYDRO-7H-PYRROLO(3,4-G)QUINOLIN-7-YL)-3-METHYLBENZYL)SULFONYL)-2-(2-METHOXYPHENYL)ACETAMIDE; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2 RECEPTOR, EP4 SUBTYPE; QUINOLINE DERIVATIVE; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRALGIA; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DIURESIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; GASTROINTESTINAL TOXICITY; GUINEA PIG; HUMAN; HUMAN CELL; INTESTINE MUCOSA; MALE; NATRIURESIS; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; RAT; RHEUMATOID ARTHRITIS; ANIMAL; ARTHRITIS; CELL LINE; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG POTENTIATION; GENETICS; INFLAMMATION; KIDNEY; METABOLISM; PAIN; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CELL LINE; CELL LINE, TUMOR; CYCLIC AMP; CYCLOOXYGENASE 2; FUROSEMIDE; GUINEA PIGS; HUMANS; INFLAMMATION; KIDNEY; MALE; NATRIURESIS; OSTEOARTHRITIS; PAIN; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PROSTAGLANDIN E; RNA, MESSENGER; SULFONAMIDES;

EID: 42449158937     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.134510     Document Type: Article

References (41)

1. Abramovitz M, Adam M, Boie Y, Carriere M, Denis D, Godbout C, Lamontagne S, Rochette C, Sawyer N, Tremblay NM, et al. (2000) The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta 1483:285-293.
2. Amano H, Hayashi I, Endo H, Kitasato H, Yamashina S, Maruyama T, Kobayashi M, Satoh K, Narita M, Sugimoto Y, et al. (2003) Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med 197:221-232.
3. Aoi M, Aihara E, Nakashima M, and Takeuchi K (2004) Participation of prostaglandin E receptor EP4 subtype in duodenal bicarbonate secretion in rats. Am J Physiol Gastrointest Liver Physiol 287:G96-G103.
4. Bertin P, Lapicque F, Payan E, Rigaud M, Bailleul F, Jaeger S, Treves R, and Netter P (1994) Sodium naproxen: concentration and effect on inflammatory response mediators in human rheumatoid synovial fluid. Eur J Clin Pharmacol 46:3-7.
5. Burch JD, Belley M, Fortin R, Deschenes D, Girard M, Colucci J, Farand J, Therien AG, Mathieu MC, Denis D, et al. (2008) Structure-activity relationships and pharmacokinetic parameters of quinoline acylsulfonamides as potent and selective antagonists of the EP(4) receptor. Bioorg Med Chem Lett 18:2048-2054.
6. Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, et al. (1999) Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 290:551-560.
7. Chan CC, Boyce S, Brideau C, Ford-Hutchinson AW, Gordon R, Guay D, Hill RG, Li CS, Mancini J, and Penneton M (1995) Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharmacol Exp Ther 274:1531-1537.
8. 2 production in the rat adjuvant-induced arthritis model. J Immunol 170:4738-4744.
9. Côté B, Boulet L, Brideau C, Claveau D, Ethier D, Frenette R, Gagnon M, Giroux A, Guay J, Guiral S, et al. (2007) Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors. Bioorg Med Chem Lett 17:6816-6820.
10. Curtis SP, Ng J, Yu Q, Shingo S, Bergman G, McCormick CL, and Reicin AS (2004) Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials. Clin Ther 26:70-83.
11. Ducharme Y, Blouin M, Carriere MC, Chateauneuf A, Cote B, Denis D, Frenette R, Greig G, Kargman S, Lamontagne S, et al. (2005) 2,3-Diarylthiophenes as selective EP1 receptor antagonists. Bioorg Med Chem Lett 15:1155-1160.
12. Fitzgerald GA (2004) Coxibs and cardiovascular disease. N Engl J Med 351:1709-1711.
13. Francois H, Athirakul K, Howell D, Dash R, Mao L, Kim HS, Rockman HA, Fitzgerald GA, Koller BH, and Coffman TM (2005) Prostacyclin protects against elevated blood pressure and cardiac fibrosis. Cell Metab 2:201-207.
14. Gardner DL (1994) Problems and paradigms in joint pathology. J Anat 184:465-476.
15. Giblin GM, Bit RA, Brown SH, Chaignot HM, Chowdhury A, Chessell IP, Clayton NM, Coleman T, Hall A, Hammond B, et al. (2007) The discovery of 6-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclopenten-1- yl]-2-pyridinecarboxylic acid, GW848687X, a potent and selective prostaglandin EP1 receptor antagonist for the treatment of inflammatory pain. Bioorg Med Chem Lett 17:385-389.
16. Hochberg MC (2005) COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective. Curr Top Med Chem 5:443-448.
17. 2-EP2/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis. J Exp Med 203:325-335.
18. 2 protects gastric mucosal cells from apoptosis via EP2 and EP4 receptor activation. J Biol Chem 278:12752-12758.
19. Juteau H, Gareau Y, Labelle M, Sturino CF, Sawyer N, Tremblay N, Lamontagne S, Carriere MC, Denis D, and Metters KM (2001) Structure-activity relationship of cinnamic acylsulfonamide analogues on the human EP3 prostanoid receptor. Bioorg Med Chem 9:1977-1984.
20. Kennedy CR, Zhang Y, Brandon S, Guan Y, Coffee K, Funk CD, Magnuson MA, Oates JA, Breyer MD, and Breyer RM (1999) Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Nat Med 5:217-220.
21. 2 biosynthetic pathway. Arthritis Rheum 52:3439-3447.
22. Kurihara Y, Endo H, Akahoshi T, and Kondo H (2001) Up-regulation of prostaglandin E receptor EP2 and EP4 subtypes in rat synovial tissues with adjuvant arthritis. Clin Exp Immunol 123:323-330.
23. Larsen R, Hansen MB, and Bindslev N (2005) Duodenal secretion in humans mediated by the EP4 receptor subtype. Acta Physiol Scand 185:133-140.
24. 2 receptor EP4 contributes to inflammatory pain hypersensitivity. J Pharmacol Exp Ther 319:1096-1103.
25. 2 receptors in the pathogenesis of rheumatoid arthritis. J Clin Invest 110:651-658.
26. Myers LK, Kang AH, Postlethwaite AE, Rosloniec EF, Morham SG, Shlopov BV, Goorha S, and Ballou LR (2000) The genetic ablation of cyclooxygenase 2 prevents the development of autoimmune arthritis. Arthritis Rheum 43:2687-2693.
27. Nakao K, Murase A, Ohshiro H, Okumura T, Taniguchi K, Murata Y, Masuda M, Kato T, Okumura Y, and Takada J (2007) CJ-023,423, a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties. J Pharmacol Exp Ther 322:686-694.
28. 2 EP4 receptor in furosemide-induced salt-losing tubulopathy: a model for hyperprostaglandin E syndrome/antenatal Bartter syndrome. J Am Soc Nephrol 16:2354-2362.
29. 2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo. J Exp Med 184:883-891.
30. Pulichino AM, Rowland S, Wu T, Clark P, Xu D, Mathieu MC, Riendeau D, and Audoly LP (2006) Prostacyclin antagonism reduces pain and inflammation in rodent models of hyperalgesia and chronic arthritis. J Pharmacol Exp Ther 319:1043-1050.
31. Rowland SE, Clark P, Gordon R, Mullen AK, Guay J, Dufresne L, Brideau C, Cote B, Ducharme Y, Mancini J, et al. (2007) Pharmacological characterization of a selective COX-2 inhibitor MF-tricyclic, [3-(3,4-difluorophenyl)-4-(4- (methylsulfonyl-)phenyl)-2-(5H)-furanone], in multiple preclinical species. Eur J Pharmacol 560:216-224.
32. Seppälä E, Nissila M, Isomaki H, Nuotio P, Nykanen E, Laitinen O, and Vapaatalo H (1985) Comparison of the effects of different anti-inflammatory drugs on synovial fluid prostanoid concentrations in patients with rheumatoid arthritis. Clin Rheumatol 4:315-320.
33. 2-stimulated mucus secretion by rabbit gastric epithelial cells. Biochem Pharmacol 58:1997-2002.
34. Takeuchi K, Tanaka A, Kato S, Aihara E, and Amagase K (2007) Effect of (S)-4-(1-(5-chloro-2-(4-fluorophenyoxy)benzamido)ethyl) benzoic acid (CJ-42794), a selective antagonist of prostaglandin E receptor subtype 4, on ulcerogenic and healing responses in rat gastrointestinal mucosa. J Pharmacol Exp Ther 322:903-912.
35. Trebino CE, Stock JL, Gibbons CP, Naiman BM, Wachtmann TS, Umland JP, Pandher K, Lapointe JM, Saha S, Roach ML, et al. (2003) Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc Natl Acad Sci U S A 100:9044-9049.
36. Ungrin MD, Singh LM, Stocco R, Sas DE, and Abramovitz M (1999) An automated aequorin luminescence-based functional calcium assay for G-protein-coupled receptors. Anal Biochem 272:34-42.
37. 2 on renal function. Hypertension 30:664-666.
38. Wang M, Zukas AM, Hui Y, Ricciotti E, Pure E, and Fitzgerald GA (2006) Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc Natl Acad Sci U S A 103:14507-14512.
39. Westman M, Korotkova M, af Klint E, Stark A, Audoly LP, Klareskog L, Ulfgren AK, and Jakobsson PJ (2004) Expression of microsomal prostaglandin E synthase 1 in rheumatoid arthritis synovium. Arthritis Rheum 50:1774-1780.
40. Yoshida T, Sakamoto H, Horiuchi T, Yamamoto S, Suematsu A, Oda H, and Koshihara Y (2001) Involvement of prostaglandin E(2) in interleukin-1alpha- induced parathyroid hormone-related peptide production in synovial fibroblasts of patients with rheumatoid arthritis. J Clin Endocrinol Metab 86:3272-3278.
41. Young RN, Billot X, Han Y, Slipetz DA, Chauret N, Belley M, Metters K, Mathieu M-C, Greig GM, Denis D, et al. (2004) Discovery and synthesis of a potent, selective and orally bioavailable EP4 receptor agonist. Heterocycles 64:437-446.